Van Der Graaf WTA - Search Results

1

Predictors for doxorubicin-induced hematological toxicity and its association with outcome in advanced soft tissue sarcoma patients; a retrospective analysis of the EORTC-soft tissue and bone sarcoma group database.

Sleijfer S, Rizzo E, Litière S, Mathijssen RHJ, Judson IR, Gelderblom H, Van Der Graaf WTA, Gronchi A. Sleijfer S, et al. Among authors: van der graaf wta. Acta Oncol. 2018 Aug;57(8):1117-1126. doi: 10.1080/0284186X.2018.1449248. Epub 2018 Mar 9. Acta Oncol. 2018. PMID: 29521151 Free article.

2

High-dose methotrexate, vincristine and cisplatin as salvage treatment for relapsed non-seminomatous germ-cell cancer.

Sleijfer S, Van der Graaf WT, Willemse PH, De Vries EG, Schraffordt Koops H, Mulder NH. Sleijfer S, et al. Anticancer Res. 1995 May-Jun;15(3):1039-42. Anticancer Res. 1995. PMID: 7544087 Clinical Trial.

3

Treatment of advanced seminoma with cyclophosphamide, vincristine and carboplatin on an outpatient basis.

Sleijfer S, Willemse PH, de Vries EG, van der Graaf WT, Schraffordt Koops H, Mulder NH. Sleijfer S, et al. Br J Cancer. 1996 Sep;74(6):947-50. doi: 10.1038/bjc.1996.462. Br J Cancer. 1996. PMID: 8826863 Free PMC article.

4

Successful treatment on an out-patient basis of a patient with Down's syndrome and disseminated testicular seminoma.

Sleijfer S, Koops HS, van der Graaf WT. Sleijfer S, et al. Neth J Med. 1996 Mar;48(3):89-91. doi: 10.1016/0300-2977(95)00058-5. Neth J Med. 1996. PMID: 8935748

5

Seizures in a patient with disseminated testicular cancer due to cisplatin-induced hypomagnesaemia.

van de Loosdrecht AA, Gietema JA, van der Graaf WT. van de Loosdrecht AA, et al. Acta Oncol. 2000;39(2):239-40. doi: 10.1080/028418600430851. Acta Oncol. 2000. PMID: 10859019 No abstract available.

6

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study.

Verweij J, van Oosterom A, Blay JY, Judson I, Rodenhuis S, van der Graaf W, Radford J, Le Cesne A, Hogendoorn PC, di Paola ED, Brown M, Nielsen OS. Verweij J, et al. Eur J Cancer. 2003 Sep;39(14):2006-11. Eur J Cancer. 2003. PMID: 12957454 Clinical Trial.

7

[Imatinib, a specific tyrosine-kinase inhibitor, for the treatment of patients with a gastrointestinal stroma cell tumor].

Gelderblom H, Hogendoorn PC, van der Graaf WT, Verweij J. Gelderblom H, et al. Ned Tijdschr Geneeskd. 2003 Oct 18;147(42):2051-5. Ned Tijdschr Geneeskd. 2003. PMID: 14606351 Review. Dutch.

8

Angiogenesis inhibition in non-GIST soft tissue sarcomas.

Sleijfer S, van der Graaf WT, Blay JY. Sleijfer S, et al. Oncologist. 2008 Nov;13(11):1193-200. doi: 10.1634/theoncologist.2008-0188. Epub 2008 Nov 5. Oncologist. 2008. PMID: 18987047 Free article. Review.

9

Case studies showing clinical signs and management of cutaneous toxicity of the MEK1/2 inhibitor AZD6244 (ARRY-142886) in patients with solid tumours.

Desar IM, Bovenschen HJ, Timmer-Bonte AJ, Cantarini MV, Van Der Graaf WT, Van Rossum MM, Van Herpen CM. Desar IM, et al. Acta Oncol. 2010;49(1):110-3. doi: 10.3109/02841860903104152. Acta Oncol. 2010. PMID: 19634052 No abstract available.

10

Anaplastic lymphoma kinase aberrations in rhabdomyosarcoma: clinical and prognostic implications.

van Gaal JC, Flucke UE, Roeffen MH, de Bont ES, Sleijfer S, Mavinkurve-Groothuis AM, Suurmeijer AJ, van der Graaf WT, Versleijen-Jonkers YM. van Gaal JC, et al. J Clin Oncol. 2012 Jan 20;30(3):308-15. doi: 10.1200/JCO.2011.37.8588. Epub 2011 Dec 19. J Clin Oncol. 2012. PMID: 22184391

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

637 results

Search Page

Filters